



 [Update Your Profile](#)

Wilbur H. Chen, MD, MS

Academic Title:

Associate Professor

Primary Appointment:

Medicine

Email:

wchen@som.umaryland.edu

Location:

HSF1, 480

Phone (Primary):

(410) 706-5328

Fax:

(410) 706-6205

[Download CV](#)

Education and Training

Boston University, B.A., Biology, 1992

Howard University College of Medicine, M.D., 1999

Residency, Johns Hopkins University Bayview Medical Center, Internal Medicine, 1999-2002

Fellowship, University of Maryland Medical Center, Infectious Diseases, 2002-2004

Fellowship, University of Maryland Center for Vaccine Development, National Research Service Award in Vaccinology, 2004-2006

University of Maryland, M.S., Clinical Research, 2008

Biosketch

Dr. Chen is an adult infectious disease physician-scientist with a specific interest in clinical vaccinology. He is Chief of the Adult Clinical Studies section within the [Center for Vaccine Development](#) and Director of the [UMB Travel Medicine Practice](#). His research is concentrated on two areas of global health importance. First, he is devoted to developing vaccines for enteric pathogens, infectious diseases chiefly of resource poor and economically disadvantaged countries and populations. Second, he is interested in developing improved vaccines for the elderly, a rapidly growing segment of the global population which is susceptible to many infections and a special population that generally responds poorly to vaccination.

Dr. Chen is active investigator within the NIAID-supported [Vaccine and Treatment Evaluation Unit](#) (VTEU), composed of 9 academic centers throughout the U.S., and was the principal investigator of the NIAID-supported Food and Waterborne Diseases Integrated Research Network Clinical Research Unit (FWD IRN CRU). He has been a PI on vaccine trials for: influenza viruses (Seasonal, Pandemic 2009 H1N1, Avian H5N1, and Avian H7N9 influenza), agents of bioterror (Tularemia and Staphylococcal enterotoxin B), and enteric pathogens (typhoid, cholera and enterotoxigenic *E. coli*)-including human experimental challenge studies with wild-type *V. cholerae* and enterotoxigenic *E. coli* (ETEC).

In collaboration with [PATH](#) (an international nonprofit organization, Program for Appropriate Technology in Health), Dr. Chen has imminent research projects evaluating a meningococcal vaccine, *Shigella* vaccines, and developing a human challenge model with heat-stable enterotoxin (ST)-only expressing ETEC. With funding from the [Bill & Melinda Gates Foundation](#), Dr. Chen is also developing a human challenge model with *Cryptosporidium hominis*.

Research/Clinical Keywords

Infectious diseases, vaccinology, clinical trials, enteric pathogens, ETEC, influenza, meningitis, shigella, bioterrorism, human challenge model, and VTEU.

Highlighted Publications

Hoft DF, Lottenbach K, Goll JB, Hill H, Winokur PL, Patel SM, Brady RC, **Chen WH**, Edwards K, Creech CB, Frey SE, Blevins TP, Salomon R, Belshe RB. [Priming vaccination with H5 hemagglutinin antigen significantly increases T cell responses induced by a heterologous H5 booster vaccination](#). *J Infect Dis*. 2016; 214(7):1020-1029.

Feldstein LR, Matrajt L, Halloran ME, Keitel WA, Longini IM; member of H5N1 Vaccine Working Group. [Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies](#). *Vaccine* 2016; 34:3796-802.

Tapia MD, Sow SO, Tamoura B, Teguate I, Pasetti MF, Kodio M, Onwuchekwa U, Tennant SM, Blackwelder WC, Coulibaly F, Traore A, Keita AM, Haidara FC, Diallo F, Doumbia M, Sanogo D, EdMatt E, Schluterman NH, Buchwald A, Kotloff KL, **Chen WH**, Orenstein EW, Orenstein LAV, Villanueva J, Bresee J, Treanor J, Levine MM. [Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: A](#)

[prospective, active-controlled, observer-blind, randomised phase 4 trial](#). *Lancet Infect Dis*. 2016; 16(9):1026-1035.

Chen WH, Cohen MB, Kirkpatrick, BD, Brady RC, Galloway D, Gurwith M, Hall RH, Kessler RA, Lock M, Haney D, Lyon CE, Simon JK, Szabo F, Levine MM. [Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor](#). *Clin Infect Dis* 2016; 62:1329-35.

Mbawuike I, Atmar RL, Patel SM, Corry D, Winokur PL, Brady RC, **Chen WH**, Edwards KM, Creech CB, Walter EB, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA. [Cell mediated immune responses following revaccination with an Influenza A/H5N1 vaccine](#) . *Vaccine* 2016; 34:547-554.

 [Update Your Profile](#)